Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Healthtrust
Daiichi Sankyo
US Department of Justice
Boehringer Ingelheim
Queensland Health
McKesson
Medtronic
Johnson and Johnson

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

« Back to Dashboard

Clinical Trials for Olmesartan Medoxomil And Hydrochlorothiazide

Trial ID Title Status Sponsor Phase Summary
NCT00139698 Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension Completed Pfizer Phase 3 Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
NCT00171015 VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil Completed Novartis Phase 3 To evaluate the efficacy of valsartan 160 mg/HCTZ 25 mg in patients not adequately responding to monotherapy with olmesartan medoxomil 40 mg or combination therapy with olmesartan medoxomil 20 mg plus HCTZ 12.5 mg by testing the hypothesis that valsartan 160 mg/HCTZ 25 mg significantly reduces the trough mean sitting diastolic blood pressure (MSDBP) after a 4-week treatment in the nonresponder population.
NCT00185068 An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension Completed Daiichi Sankyo Inc. Phase 4 Effect of increasing doses of olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide on blood pressure in patients with hypertension
NCT00185120 Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker Completed Daiichi Sankyo Inc. Phase 4 A comparison of 2 different combinations of high blood pressure medications to treat hypertension
NCT00311155 Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension Completed Sankyo Pharma Gmbh Phase 4 This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension.
NCT00430508 Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension Completed Daiichi Sankyo Europe, GmbH Phase 3 The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.
NCT00430508 Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension Completed Daiichi Sankyo Inc. Phase 3 The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Olmesartan Medoxomil And Hydrochlorothiazide

Condition Name

Condition Name for Olmesartan Medoxomil And Hydrochlorothiazide
Intervention Trials
Essential Hypertension 12
Hypertension 7
Healthy Subjects 2
Healthy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Olmesartan Medoxomil And Hydrochlorothiazide
Intervention Trials
Hypertension 19
Kidney Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Olmesartan Medoxomil And Hydrochlorothiazide

Trials by Country

Trials by Country for Olmesartan Medoxomil And Hydrochlorothiazide
Location Trials
United States 150
Germany 15
Netherlands 10
Poland 7
Mexico 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Olmesartan Medoxomil And Hydrochlorothiazide
Location Trials
Florida 6
California 6
Texas 5
Ohio 5
North Carolina 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Olmesartan Medoxomil And Hydrochlorothiazide

Clinical Trial Phase

Clinical Trial Phase for Olmesartan Medoxomil And Hydrochlorothiazide
Clinical Trial Phase Trials
Phase 4 6
Phase 3 15
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Olmesartan Medoxomil And Hydrochlorothiazide
Clinical Trial Phase Trials
Completed 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Olmesartan Medoxomil And Hydrochlorothiazide

Sponsor Name

Sponsor Name for Olmesartan Medoxomil And Hydrochlorothiazide
Sponsor Trials
Daiichi Sankyo Inc. 9
Daiichi Sankyo Europe, GmbH 5
Takeda 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Olmesartan Medoxomil And Hydrochlorothiazide
Sponsor Trials
Industry 29
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Accenture
UBS
Julphar
AstraZeneca
Johnson and Johnson
Chinese Patent Office
Farmers Insurance
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.